drugset / Trial / NCT02239224
Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess the safety and tolerability profile of ATYR1940 in the treatment of adult participants with molecularly defined genetic muscular dystrophies
Timeline
- Start
- 2014-09-04
- Primary completion
- 2015-12-14
- Completion
- 2015-12-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATYR1940 | Unknown | 0.3 mg/kg | Intravenous |
| Subject | ATYR1940 | Unknown | 1 mg/kg | Intravenous |
| Subject | ATYR1940 | Unknown | 3 mg/kg | Intravenous |